Press Releases

Inizio Medical Appoints Patrick Giordani as SVP, AI Solutions Architect, Underpinning Commitment to Expanding AI Capabilities and Accelerating Innovation

ProPharma Appoints Brian Tuttle as Chief Financial Officer

Seasoned Life Sciences Executive to Spearhead Financial Strategy and Drive Accelerated Growth

CovarsaDx Welcomes Rich Masino as Senior Director of Strategic Partnerships and Business Development

CovarsaDx, a clinical research organization at the forefront of in vitro diagnostics (IVD) and medical device trials, has appointed Rich Masino as senior director of strategic partnerships and business development. Bringing over 30 years of experience in biotech, pharma, and medical device diagnostics, Masino will focus on driving growth and forging strategic partnerships across CovarsaDx and ZoaDx, while reporting directly to the company’s chief executive officer (CEO).

Biotech Capital on the Rise and Outsourcing to Accelerate in 2025 - but Uneven Growth for CDMOs

PHARMASEAL AND LEDGER RUN FORGE PARTNERSHIP TO ENHANCE CLINICAL BUSINESS OPERATIONS

PHARMASEAL specializes in state-of-the-art trial management software for life sciences (unified CTMS/eTMF) and LEDGER RUN, INC., an innovative technology company focused on optimizing clinical operations in the areas of site budgeting, contracts and payments, announced their partnership today. Through the partnership, PHARMASEAL’S Engility® Platform software Engility CTMS, Engility eTMF and LEDGER RUN'S unique ClinRun™ platform will streamline and enhance clinical operation budgeting and payment processes with an intelligent approach and seamless integration.

Inizio Medical Appoints Matt Wadyka as President, US Medical Affairs

Clario and PathAI Collaborate to Deliver Integrated Solution for GI Clinical Trials

Partnership combines revolutionary digital pathology and endoscopy solutions, enhancing drug development for IBD and other GI disorders ▪ Strategic Partnership: Streamlined, single-vendor solution, promises to improve diagnostic accuracy, boost efficiency, and enable reliable turnaround times in gastrointestinal (GI) clinical trials. ▪ Advanced GI Solutions: Enhances trial efficiency with AI-powered solutions, including reading for ulcerative colitis (UC) from Clario and histopathology services from PathAI. ▪ Integrated Workflow: Combines endoscopic and histopathology endpoints with simplified processes for CROs, sponsors, and investigational sites.

Coronado Research announce engagement of Rob Nichols to support the growth of their Clinical Technology Practice

Coronado Research announced the engagement of Rob Nichols to support the build-out of its clinical technology practice and advise the executive leadership team as they deliver the broader company vision.

CovarsaDx Expands Collaborative Efforts Through MDIC Membership and Key Initiatives

CovarsaDx, a prominent Clinical Research Organization (CRO) renowned for its expertise in vitro diagnostics (IVDs) and medical devices, is proud to announce its membership in the Medical Device Innovation Consortium (MDIC). This partnership marks a significant milestone in CovarsaDx’s ongoing mission to advance innovation in healthcare technology by providing reliable clinical validation results from an elite network of experienced investigators.

ProPharma Names Dawn Sherman Chief Executive Officer

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review

CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise software platform

CRDSA Announces Publication of Standards for Clinical Trial Data Reuse

The Clinical Research Data Sharing Alliance (CRDSA), a multi-stakeholder consortium that serves the clinical research data ecosystem, has announced the publication of two new standards; the Standard for Sharing Clinical Study Data and the Standard for Secondary Analysis of Clinical Study Data. CRDSA developed these standards in response to common challenges faced by both data contributors and researchers. These new standards aim to facilitate the responsible sharing and use of anonymized individual patient data from clinical studies to support the research community and accelerate the discovery and delivery of new therapies to patients.

Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial

Duke Street Bio Ltd has announced that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.

Phastar Announced as 2024 Scrip Award Finalist for Best Contract Research Organization – Specialist Provider

Phastar’s Data Analytics and Visualization Portal and commitment to high ESG standards secures shortlist spot at the 20th Anniversary Scrip Awards

Headlands Research to Open New Clinical Research Site in El Paso, Texas, Further Commitment to Improving Diversity in Clinical Research

Headlands Research, a leading multinational network of clinical trial sites, today announced it will launch a new clinical research site in El Paso, Texas in Q4, expanding clinical trial access to a large, traditionally underserved Hispanic population. The site will focus on metabolic/endocrine, healthy volunteer/vaccine, and pain clinical trials.

eClinical Solutions Announces Growth Investment by GI Partners to Further Its Mission of Helping Bring Treatments to Patients Faster

eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that GI Partners, a private investment firm, has made a majority investment in the company to advance the future of digital trials via continued enhancements to its leading AI-powered data products and biometrics services.

Quotient Sciences and Vasa Therapeutics Announce Dosing of First Subjects with VS-041, a Novel Heart Failure Treatment

PharmaForceIQ Announces Majority Investment by Eir Partners to Support and Accelerate Growth

PharmaForceIQ Announces Majority Investment by Eir Partners to Support and Accelerate Growth Miami, FL – 10th September 2024, PharmaForceIQ (PFIQ), the leading end to end Omnichannel Solution for Pharmaceutical Marketing, Medical and Clinical teams today announced a significant investment by Eir Partners (Eir) to accelerate adoption of the company’s unique technology platform and services for the Life Science industry.

Symbiosis announces acquisition of new facility and investment in automated commercial scale GMP sterile manufacturing capability supported by £4.3m grant from Scottish Enterprise

Global CDMO brings technological advancements & significant capacity to Ocean County, NJ location